Ke He (何锞)
Deputy Director & Head of Skin & Laser Aesthetics · Attending Physician, Licensed Aesthetic Attending · Lead Physician of This Site
Cell and tissue products, and what they are approved for · the difference between a laboratory finding and a visible result · the reversible options where a change is wanted
Dr. Ke He is Deputy Director of the Plastic Surgery & Aesthetics Medical Center at Chongqing West District Hospital and head of its skin and laser aesthetic service — and she is the lead physician of this site. A core specialist formerly at the Plastic and Aesthetic Surgery Department of Xinqiao Hospital, affiliated with Army Medical University, she has worked on the clinical front line in skin laser and injectable aesthetics for more than 20 years, serving over ten thousand patients.
On this review his part is the separation of two things that share a name. He describes transplantation as established medicine with named indications and a laboratory behind it, and the cosmetic products as a different category that borrows the vocabulary without the structure, and he will not let the two be discussed as one subject. His test for any claim is what would be present if it were established: a defined product, a measured dose, a comparison group, an assessment made by somebody who does not know which treatment was given. Where a claim has none of those, he says it has none of them rather than describing the rationale as promising. Because an unapproved preparation usually cannot be identified or dissolved afterwards, he sets out how a complication would be managed before it happens, and where a reversible option would answer the question he says so instead of leaving the choice framed as cells or nothing.
Clinical focus
Academic roles & achievements
The word is doing the work, not the product
A phrase that can be applied to fat, to blood, to a plant extract and to a laboratory culture stops identifying anything. The first useful question is therefore not whether stem cell language is accurate but what specific thing is being offered, which regulatory class it sits in, and what has been assessed about that particular thing. That is the order this review follows.
